Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Pranay Prabhakar

Hospitalist Atlanta, GA Medical Doctor

NPI 1942696471 CMS profile 5597336

1364 Clifton Rd Ne, Atlanta, GA 30322

Open in the dashboard

General payments

$3,716

91 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Pranay Prabhakar of Atlanta, GA is reported in the CMS Open Payments database as having received $3,716 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $905 23
2022 General $1,616 52
2021 General $1,041 14
2020 General $155 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pranay Prabhakar
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Pranay Prabhakar were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Pranay Prabhakar Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $155 $48 $19–$125 $114
2021 $1,041 $70 $23–$167 $132
2022 $1,616 $85 $27–$174 $149
2023 $905 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. AstraZeneca Pharmaceuticals LP $591 11 payments
  2. Amgen Inc. $519 15 payments
  3. Janssen Pharmaceuticals, Inc $372 7 payments
  4. Abbott Laboratories $358 2 payments
  5. Novartis Pharmaceuticals Corporation $286 13 payments
  6. Alnylam Pharmaceuticals Inc. $267 11 payments
  7. Regeneron Healthcare Solutions, Inc. $242 2 payments
  8. Chiesi USA, Inc. $191 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $189 7 payments
  10. Pfizer Inc. $175 7 payments
  11. Other $526 12 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $3,353 88 payments
  2. Education $363 3 payments
Products named General payments · program years 2020–2023
  1. Repatha $519 15 payments
  2. XARELTO $372 7 payments
  3. FARXIGA $354 6 payments
  4. ONPATTRO $267 11 payments
  5. EVKEEZA $242 2 payments
  6. EnSite Precision Cardiac Mapping System $208 1 payment
  7. LEQVIO $192 8 payments
  8. KENGREAL $191 4 payments
  9. JARDIANCE $189 7 payments
  10. HeartMate Touch $150 1 payment
  11. Other $1,095 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

417

Median for Internal Medicine: 777

Drug cost

$72,581

Median for Internal Medicine: $73,373

Branded share of claims

14.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 46 $52,869
Xarelto Rivaroxaban Brand 14 $13,289
Metoprolol Succinate Generic 109 $2,335
Ezetimibe Generic 38 $1,695
Atorvastatin Calcium Generic 105 $1,331
Rosuvastatin Calcium Generic 15 $488
Carvedilol Generic 22 $181
Amlodipine Besylate Generic 25 $163
Lisinopril Generic 24 $145
Furosemide Generic 19 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$135,037

Medicare's payments for the services billed

Medicare patients

2,208

Average age 76

Services billed

3,680

1,219 women, 989 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 45%
Chronic kidney disease 43%
Depression 38%
Heart failure 36%
Atrial fibrillation 36%
Diabetes 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record